March 28th 2024
The benefits noted in this exploratory analysis were irrespective of the number of neoadjuvant treatment cycles completed in patients with resectable non-small cell lung cancer.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
The Latest on Acute Lymphocytic Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
A Focus on Acute Myeloid Leukemia
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Symptom Burden Higher in Newly Diagnosed Patients Reporting Financial Strain
March 25th 2016A study published by researchers at the Dana Farber-Cancer Institute recently discovered that financial status plays a large role in the level of symptom burden and quality of life for patients newly diagnosed with lung or colorectal cancer.
Changing the Face of Lung Cancer in Kentucky: New Program May Serve as National Model
December 23rd 2015Lung cancer remains the leading cause of cancer mortality, killing more Americans than breast, colon, and prostate cancer combined—and Kentucky is the epicenter of lung cancer in the United States.
For Patients With Lung Cancer, New Therapies Offer Reason to Hope
December 15th 2015FDA approval of two immunotherapies to treat non-small cell lung cancer (NSCLC), an ever-expanding understanding of the disease’s molecular differences, and new screening guidelines for high-risk patients to detect lung cancer at an earlier, more treatable stage, are helping patients live longer.
Improving Outcomes in Lung Cancer With Multidisciplinary Care
December 3rd 2015Navigation is an essential component of quality care for patients with lung cancer and their family caregivers, and the Bonnie J. Addario Lung Cancer Foundation (ALCF) is working to improve lung cancer outcomes through its Community Hospital Center of Excellence (COE) program.
Portrazza FDA approved for Advanced Squamous NSCLC
November 24th 2015The combination of Portrazza (necitumumab) with gemcitabine and cisplatin has been FDA approved as first-line therapy for patients with locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC). The approval is based on findings from the phase III SQUIRE trial.
FDA Approves Osimertinib Ahead of Schedule for Advanced NSCLC
November 13th 2015The FDA has granted an accelerated approval for Tagrisso (osimertinib) to treat patients with advanced non–small cell lung cancer (NSCLC) positive the EGFR T790M mutation and whose disease worsened following a prior EGFR TKI.
Aprepitant Shows Promise for Managing Cough in Lung Cancer
October 12th 2015The antiemetic NK-1 antagonist aprepitant (Emend) was shown to significantly reduce cough in patients with lung cancer, according to findings of the first antitussive trial in patients with lung cancer using objective quantification of cough.
Most Young Lung Cancer Patients Have Actionable Mutations
September 9th 2015A preliminary analysis of an ongoing study shows that most patients diagnosed with lung cancer before age 40 had an increased chance for a targeted genomic alteration, knowledge of which could lead to more effective, targeted treatment.